scholarly journals Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China

2017 ◽  
Vol 13 (5) ◽  
pp. 3163-3168 ◽  
Author(s):  
Kaizhou Jin ◽  
Guopei Luo ◽  
Jin Xu ◽  
Bo Zhang ◽  
Chen Liu ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Clinical Outcomes ◽  
Neuroendocrine Neoplasms ◽  
Single Center ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Single Center Experience

scholarly journals Clinical outcomes and prognostic factors of adult’s Ewing sarcoma family of tumors: single center experience

2016 ◽  
Vol 2 ◽  
pp. 141-146 ◽  
Author(s):  
Ummugul Uyeturk ◽  
Kaan Helvaci ◽  
Ayse Demirci ◽  
Ozlem Uysal Sonmez ◽  
Ibrahim Turker ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Clinical Outcomes ◽  
Ewing Sarcoma ◽  
Single Center ◽  
Single Center Experience

scholarly journals Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience

2021 ◽  
pp. 089719002110282
Author(s):  
Karan Raja ◽  
Nicole Daniel ◽  
Susan Morrison ◽  
Ruben Patel ◽  
Jessica Gerges ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Clinical Status ◽  
Rank Test ◽  
Cytokine Release ◽  
Cytokine Release Syndrome ◽  
Single Center ◽  
Post Dose ◽  
Single Center Experience ◽  
Signed Rank Test ◽  
The Impact

Background: Tocilizumab is an interleukin-6 receptor antagonist hypothesized to blunt the uncontrolled immune response, cytokine release syndrome, in severe COVID-19 and prevent attributable morbidity and mortality. Objective: The objective of this study was to assess the impact of tocilizumab on clinical outcomes in COVID-19-associated cytokine release syndrome. Methods: Single-center, retrospective cohort study assessing sixty-nine adult patients receiving tocilizumab for suspected COVID-19 cytokine release syndrome. The primary outcome was change in WHO clinical status scale on day seven post-dose analyzed using the Wilcoxon signed rank test. Secondary outcomes assessed impact of timing of administration on clinical outcome. Safety analyses included development of neutropenia, thrombocytopenia, transaminitis, and sepsis within 7 days post-dose. Statistical analyses were conducted using Microsoft Excel. Results: No aggregate clinical change was found between day 0 and day 7. Eleven patients improved, twenty-seven worsened, and thirty-one showed no change. Clinical outcomes were weakly correlated with time from symptom onset (rs = 0.21; p = 0.08) or hospital admission (rs = -0.08; p = 0.49) to dose. In-hospital mortality was 63%. Sepsis was diagnosed in 21 patients, five of which were post-dose. Transaminitis, neutropenia, and thrombocytopenia occurred in seven, one, and six patients, respectively. Conclusion: Tocilizumab did not appear to influence clinical outcomes in our study population, irrespective of timing of administration. Adverse events were not considered drug-related.

Sign in / Sign up

Export Citation Format

Share Document